These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32441894)

  • 21. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation vaccine platforms for COVID-19.
    van Riel D; de Wit E
    Nat Mater; 2020 Aug; 19(8):810-812. PubMed ID: 32704139
    [No Abstract]   [Full Text] [Related]  

  • 23. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.
    Eyal N; Lipsitch M; Smith PG
    J Infect Dis; 2020 May; 221(11):1752-1756. PubMed ID: 32232474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A strategic approach to COVID-19 vaccine R&D.
    Corey L; Mascola JR; Fauci AS; Collins FS
    Science; 2020 May; 368(6494):948-950. PubMed ID: 32393526
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 vaccine development pipeline gears up.
    Mullard A
    Lancet; 2020 Jun; 395(10239):1751-1752. PubMed ID: 32505245
    [No Abstract]   [Full Text] [Related]  

  • 26. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
    Shih HI; Wu CJ; Tu YF; Chi CY
    Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticipating Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Testing, Licensure, and Recommendations for Use.
    Edwards KM; Orenstein WA
    J Pediatr; 2020 Sep; 224():124-128. PubMed ID: 32565096
    [No Abstract]   [Full Text] [Related]  

  • 28. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
    Schaefer GO; Tam CC; Savulescu J; Voo TC
    Vaccine; 2020 Jul; 38(33):5085-5088. PubMed ID: 32540271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines.
    Moise L; Ross TM; Hoft DF; Martin WD; De Groot AS
    Expert Rev Vaccines; 2020 Sep; 19(9):781-784. PubMed ID: 32962468
    [No Abstract]   [Full Text] [Related]  

  • 30. COVID-19 therapies and vaccine landscape.
    Nat Mater; 2020 Aug; 19(8):809. PubMed ID: 32704138
    [No Abstract]   [Full Text] [Related]  

  • 31. Rapid COVID-19 vaccine development.
    Graham BS
    Science; 2020 May; 368(6494):945-946. PubMed ID: 32385100
    [No Abstract]   [Full Text] [Related]  

  • 32. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
    Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
    J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 vaccine design: the Janus face of immune enhancement.
    Hotez PJ; Corry DB; Bottazzi ME
    Nat Rev Immunol; 2020 Jun; 20(6):347-348. PubMed ID: 32346094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronavirus vaccines leap through safety trials - but which will work is anybody's guess.
    Callaway E
    Nature; 2020 Jul; 583(7818):669-670. PubMed ID: 32710003
    [No Abstract]   [Full Text] [Related]  

  • 35. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
    Mirzaei R; Mohammadzadeh R; Mahdavi F; Badrzadeh F; Kazemi S; Ebrahimi M; Soltani F; Kazemi S; Jeda AS; Darvishmotevalli M; Yousefimashouf R; Keyvani H; Karampoor S
    Int Immunopharmacol; 2020 Nov; 88():106928. PubMed ID: 32862110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Race to Develop a COVID-19 Vaccine.
    Am J Nurs; 2020 Oct; 120(10):14-15. PubMed ID: 32976132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 Vaccines: Status Report.
    Amanat F; Krammer F
    Immunity; 2020 Apr; 52(4):583-589. PubMed ID: 32259480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Status of COVID-19 vaccine development.
    Taxt AM; Grødeland G; Lind A; Müller F
    Tidsskr Nor Laegeforen; 2020 Sep; 140(13):. PubMed ID: 32998488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 and Moral Imperialism in Multinational Clinical Research.
    Hellmann F; Williams-Jones B; Garrafa V
    Arch Med Res; 2020 Aug; 51(6):572-573. PubMed ID: 32387041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Keeping track of the SARS-CoV-2 vaccine pipeline.
    Parker EPK; Shrotri M; Kampmann B
    Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.